Efficacy and safety of visepegenatide, a long-acting weekly GLP-1 receptor agonist as monotherapy in type 2 diabetes mellitus: a randomised, double-blind, parallel, placebo-controlled phase 3 trialResearch in context

• Main Authors: Xiang Yan (Author), Jianhua Ma (Author), Yan Liu (Author), Xuhong Wang (Author), Sheli Li (Author), Shuang Yan (Author), Zhaohui Mo (Author), Yikun Zhu (Author), Jingna Lin (Author), Jie Liu (Author), Ying Jia (Author), Li Liu (Author), Ke Ding (Author), Michael Xu (Author), Zhiguang Zhou (Author)
• Format: Book
• Published: Elsevier, 2024-06-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Summary: Background: Type 2 diabetes (T2DM) remains a challenge to treat despite the expansion of various therapeutic classes. Visepegenatide (PB-119) is a once a week, subcutaneous, glucagon-like peptide-1 receptor agonist (GLP-1 RA) injection without the requirement of dose titration that has show...